In Silico Molecular-Based Rationale for SARS-CoV-2 Spike Circulating Mutations Able to Escape Bamlanivimab and Etesevimab Monoclonal Antibodies
E. Laurini, D. Marson, S. Aulic, A. Fermeglia, S. PRICL
This study predicts SARS-CoV-2 spike mutations that confer resistance to bamlanivimab and etesevimab monoclonal antibodies using in silico methods, showing 90% agreement with experimental data.
bioRxiv · May 18, 2021Biophysics